LB Pharmaceuticals Presents New Data on LB-102's Potential to Improve Cognitive Performance in Schizophrenia

Analyses from Phase 2 NOVA-1 trial highlight cognitive benefits of novel antipsychotic candidate

Mar. 30, 2026 at 7:26am

LB Pharmaceuticals presented new data from the Phase 2 NOVA-1 trial of its investigational schizophrenia treatment LB-102, showcasing the drug's potential to directly improve cognitive performance in patients with acute schizophrenia. The company also shared analyses exploring LB-102's effects on different symptom domains of the disease.

Why it matters

Cognitive impairment is a core feature of schizophrenia that significantly impacts patients' daily functioning. Current antipsychotics have limited efficacy in addressing these cognitive deficits, so new therapies that can directly improve cognition would represent an important advance in the treatment of this debilitating condition.

The details

The post hoc analysis from the NOVA-1 trial demonstrated that the cognitive benefits observed with LB-102 were primarily a direct effect of the drug, rather than an indirect result of its impact on overall schizophrenia symptoms. Additionally, an encore presentation reviewed LB-102's effects across the five PANSS Marder factors, providing a more nuanced understanding of its impact on positive, negative, and other symptom domains.

  • The NOVA-1 trial data was presented at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) on March 27th.
  • LB Pharmaceuticals recently initiated a pivotal Phase 3 trial (NOVA-2) of LB-102 in acute schizophrenia, as well as a planned open-label extension study.

The players

LB Pharmaceuticals Inc.

A late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Anna Eramo, M.D.

Chief Medical Officer of LB Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“There remains significant unmet need for new schizophrenia therapies that offer patients the potential for improvements in cognitive symptoms that drive functional impairment.”

— Anna Eramo, M.D., Chief Medical Officer, LB Pharmaceuticals

What’s next

LB Pharmaceuticals is prospectively evaluating cognitive performance as a secondary endpoint in its recently initiated pivotal Phase 3 trial (NOVA-2) of LB-102 in patients with acute schizophrenia, as well as in planned open-label extension and other ongoing trials in bipolar depression and adjunctive major depressive disorder.

The takeaway

The new data on LB-102's direct cognitive benefits, combined with its potentially class-leading safety profile and effects on negative symptoms, underscore the drug's potential to address multiple dimensions of schizophrenia and represent an important advancement in the treatment of this complex neuropsychiatric disorder.